Story thread · 9 reports / 5 sources
Alnylam plunges as earnings deliver ‘one-two punch’
biopharmadive.com · 12d
How the coverage leans
Across 5 sources · syndicated copies counted once
The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.
First report: Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views — investors.com, 13d
The coverage
- Climb Global Solutions Q2 Earnings Call Highlights
finance.yahoo.com · 12d
- Alnylam: Q2 Earnings Snapshot
wtop.com · 12d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.